Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides), By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others), By Region, By Competition Forecast & Opportunities,

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 15.01 Billion

CAGR (2023-2028)

6.24%

Fastest Growing Segment

Sub-dermal Contraceptive Implants

Largest Market

North America


Market Overview

Global Female Contraceptive Market has valued at USD 15.01 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.24% through 2028. The global female contraceptive market refers to the industry that produces and distributes various contraceptive products and devices designed for women to prevent unintended pregnancies. This market has been a crucial component of women's healthcare and family planning for many years. Here are key points summarizing the state of the market up to September 2021:

Key Market Drivers

Women's Empowerment

Women's empowerment is a driving force for social change and progress, extending its influence on various sectors, including healthcare. The global female contraceptive market, vital for reproductive health and family planning, is significantly impacted by women's empowerment. Women's empowerment involves providing women with information and education about their reproductive health and contraceptive options. When women are well-informed, they can make informed choices about contraception that align with their personal goals, health needs, and lifestyles. Empowerment often comes with improved access to healthcare services. Empowered women are more likely to seek out healthcare resources, including family planning clinics and contraception. This increased demand can stimulate market growth, prompting pharmaceutical companies to invest in research and development of new and improved contraceptive options. Economic independence and empowerment enable women to afford contraceptives and family planning services. Financial autonomy allows them to make choices about their reproductive health without relying solely on their partners or family members. This financial freedom contributes to increased contraceptive usage and market growth. Empowered women are more likely to challenge and change societal norms and attitudes surrounding contraception and family planning. By advocating for reproductive rights and breaking down stigmas associated with contraceptive use, empowered women can create a more supportive environment for those seeking contraceptives. Empowerment often leads to advocacy and activism. Empowered women and organizations dedicated to women's rights can drive awareness campaigns about family planning and the importance of contraceptives. Such initiatives help educate and motivate individuals to consider contraception as a viable option. Empowered women often serve as role models within their communities. When they make informed decisions about contraception, it can inspire others to do the same. This ripple effect can contribute to a higher demand for contraceptives within communities and regions.

Growing Population and Urbanization

The global female contraceptive market has seen significant growth over the years, and one key driver of this expansion is the interplay between population growth and urbanization. As the world's population continues to increase, with a growing proportion residing in urban areas, the demand for effective family planning and female contraceptives has surged. Urbanization is accompanied by improved access to healthcare services. In urban areas, individuals often have easier access to clinics, hospitals, and family planning centers where contraceptive options are readily available. The proximity of these services encourages more people, especially women, to seek and use contraceptives. Urbanization often leads to smaller family sizes due to factors such as limited living space, higher living costs, and career aspirations. As urban families prioritize smaller and more manageable family sizes, there is a greater demand for effective contraceptives to plan and space births. Urban areas typically have better educational infrastructure, leading to increased awareness about the importance of family planning and contraceptive methods. People in urban centers are more likely to be informed about their reproductive health options and, as a result, choose to use female contraceptives to prevent unplanned pregnancies. Urbanization often brings about economic opportunities and higher standards of living. As individuals and families in urban areas strive for financial stability and career advancement, they tend to delay childbirth and prioritize contraception as a means of family planning and securing their economic future. Urban environments often promote gender equality and women's empowerment, enabling women to make choices about their reproductive health. Empowered women are more likely to seek and use contraceptives, contributing to the growth of the female contraceptive market.

Changing Social Norms

The global female contraceptive market is evolving, driven not only by advancements in technology and healthcare but also by shifting social norms and attitudes towards contraception. As societies around the world continue to evolve, so do the perceptions of family planning and reproductive health. Changing social norms is gradually reducing the stigma associated with contraception. In many societies, discussions surrounding family planning and contraceptive use were once considered taboo. However, as conversations become more open and accepting, individuals are increasingly comfortable seeking contraceptive options, thus driving market growth. Changing social norms often accompany the empowerment of women. As women gain greater control over their lives, including their reproductive choices, they are more likely to seek and use contraceptives. Empowered women are advocating for their reproductive rights and choices, contributing to an increased demand for female contraceptives. Societal changes have led to educational initiatives that promote family planning and reproductive health. These programs aim to inform both women and men about contraceptive options, benefits, and responsible family planning practices. Greater knowledge encourages the use of contraceptives, which boosts market growth. Changing norms, such as delaying parenthood to focus on careers or personal goals, have resulted in a higher demand for contraceptives. Couples are actively choosing to postpone starting families until they feel financially and emotionally prepared. This delay often requires effective contraception.

Global Health Concerns

Global health concerns have been a driving force behind the development and expansion of various healthcare sectors, and the global female contraceptive market is no exception. The growing awareness of population control, the prevention of unintended pregnancies, and the spread of sexually transmitted infections (STIs) has fueled innovation in the female contraceptive market. One of the primary global health concerns that have driven the growth of the female contraceptive market is the need for effective population control. As the world's population continues to surge, particularly in developing countries, there is a growing awareness of the strain this puts on resources, healthcare systems, and the environment. Policymakers and healthcare organizations worldwide recognize the importance of empowering women with choices for family planning. Female contraceptives offer a reliable means of controlling family size, allowing women to plan pregnancies and space them according to their preferences and circumstances. This not only leads to healthier families but also helps in curbing overpopulation, a critical issue facing many countries. The availability and accessibility of female contraceptives have thus become a priority for governments and international health organizations, driving market growth. Unintended pregnancies can have far-reaching social, economic, and health consequences. They can result in delayed education, restricted career opportunities, increased financial stress, and even higher rates of maternal and infant mortality.


Download Free Sample Report

Key Market Challenges

Limited Access and Awareness

One of the most significant challenges facing the global female contraceptive market is limited access and awareness, particularly in low-income and marginalized communities. Many women around the world still lack access to affordable and reliable contraceptives due to geographical, financial, or cultural barriers. In some cases, women are simply unaware of the available contraceptive options and their benefits.

To overcome this challenge, efforts are being made to improve education and awareness about contraceptives, especially in underserved regions. NGOs, governments, and international organizations are working together to increase access to family planning services, ensuring that women have the information and resources they need to make informed decisions about their reproductive health.

Stigma and Cultural Barriers

Cultural and societal norms can create significant barriers to contraceptive use, especially in conservative or traditional societies. Stigma surrounding contraception and the fear of judgment can deter women from seeking and using contraceptives. These cultural barriers are often deeply rooted and require comprehensive strategies to address.

To combat stigma and cultural barriers, education and advocacy campaigns are essential. These efforts aim to change societal perceptions and attitudes toward contraception while emphasizing its importance in promoting family planning and women's health. Local community engagement and culturally sensitive approaches are also crucial in addressing these challenges.

Product Safety and Side Effects

Another challenge faced by the female contraceptive market is concerns related to product safety and potential side effects. While contraceptives are generally safe and effective, some women may experience side effects or adverse reactions. The fear of these side effects can discourage some women from using contraceptives.

To address this challenge, pharmaceutical companies and healthcare providers are continually researching and developing new contraceptive methods with improved safety profiles and fewer side effects. Additionally, healthcare professionals are working to provide better counseling and support to women, helping them make informed decisions about contraceptive options based on their individual health and preferences.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

One of the most promising trends in the female contraceptive market is the development of hormonal contraceptives with reduced side effects. Pharmaceutical companies are investing in research to create contraceptives that offer effective pregnancy prevention while minimizing common side effects like weight gain, mood swings, and decreased libido. These innovations are aimed at improving the overall user experience and encouraging more women to choose hormonal contraceptives as their preferred method.

Long-Acting Reversible Contraceptives (LARCs)

Long-Acting Reversible Contraceptives (LARCs) are gaining popularity as a convenient and effective option for women. LARCs include intrauterine devices (IUDs) and contraceptive implants, which can provide contraception for several years with a single insertion. This trend is expected to continue as women seek reliable, low-maintenance contraceptive options that fit their busy lifestyles.

Digital Health and Contraceptive Apps

The integration of digital health and technology into the female contraceptive market is a noteworthy trend. Smartphone applications and wearable devices are being developed to help women track their menstrual cycles and fertility, providing valuable information for natural family planning methods. These apps offer convenience and can be used alongside traditional contraceptive methods for added assurance.

Sustainable and Eco-Friendly Contraceptives

As environmental awareness continues to grow, there is an emerging trend toward sustainable and eco-friendly contraceptive options. Manufacturers are exploring biodegradable materials and packaging, reducing waste associated with contraceptive products. Additionally, there is a focus on developing contraceptives with a minimal environmental footprint.

Segmental Insights

Contraceptive Drugs Insights

Based on the category of Contraceptive Drugs, the Oral Contraceptives segment emerged as the dominant player in the global market for female contraceptive market in 2022 for several compelling reasons. First and foremost, they offer a convenient and widely accepted method of birth control, allowing women to take charge of their reproductive health with a simple daily pill. This ease of use aligns with the busy and on-the-go lifestyles of many women today. Additionally, oral contraceptives have a well-established safety record and a relatively low incidence of side effects, making them a trusted choice for a broad spectrum of women. Moreover, ongoing research and development efforts continue to refine these medications, addressing concerns such as reducing side effects and increasing efficacy. The availability of both combination pills and progestin-only pills further caters to individual preferences and medical needs. As access to healthcare services and awareness of family planning grow worldwide, oral contraceptives are likely to maintain their dominance in the global market, offering a reliable and adaptable contraceptive option for women.

Device Insights

Anticipated growth in the female contraceptive market is expected within the sub-dermal contraceptive implants category due to several factors, including a rising incidence of unintended pregnancies, high clinical efficacy, and widespread adoption among the population. Within the sub-dermal contraceptive implants category, it is foreseen that Etonogestrel implants will experience substantial expansion. Etonogestrel, a hormone that inhibits ovulation, also induces changes in cervical mucus and the uterine lining, making it more challenging for sperm to reach the uterus and for a fertilized egg to attach. Subdermal Etonogestrel implants are employed as a contraceptive method to prevent pregnancy, with the medication contained in a small plastic rod inserted beneath the skin of the upper arm. This rod gradually releases the medication into the body, providing continuous contraception for up to three years. The market's growth is further expected to receive a boost from the increasing focus of companies on implementing various business strategies, such as launching new products, expanding product availability in different countries, engaging in mergers, and undertaking company spin-offs, during the forecast period.

Regional Insights

North America is projected to maintain its dominance in the female contraceptive devices market throughout the forecast period, primarily due to several factors. These include the increasing instances of unintended pregnancies and high abortion rates, the presence of advanced healthcare infrastructure, a high rate of adoption of contraceptive drugs and devices, and a growing number of government initiatives. A significant portion of the female population in the United States and Canada falls within the reproductive age group. Consequently, the rising occurrences of unwanted pregnancies and abortion rates play a pivotal role in propelling market expansion in the region. For instance, data from the Guttmacher Institute in March 2022 revealed that between 2015 and 2019, North America witnessed a total of 5,660,000 pregnancies annually, with 2,590,000 of them being unwanted, and 886,000 resulting in abortion. Moreover, statistics published by the Pew Research Center in June 2022 showed an increase in abortion cases, with 930,160 recorded in the United States in 2020 compared to 916,460 in 2019. This surge in abortion cases is anticipated to drive the demand for various contraceptive methods to prevent unwanted pregnancies, thereby fueling market growth.


Download Free Sample Report

Recent Developments   

  • In April of 2022, ProMed Pharma initiated preclinical testing of an innovative, entirely bioabsorbable contraceptive implant following financial support from the Bill & Melinda Gates Foundation.
  • In January 2022, Organon unveiled plans for the public listing of NEXPLANON (an extended-release subdermal implant containing etonogestrel) in Ontario (Ontario Drug Benefit Program), British Columbia (BC PharmaCare), and Nova Scotia (Nova Scotia PharmaCare).
  • In November 2021, Organon disclosed its intent to publicly list NEXPLANON in Quebec, through the Régie de l'assurance Maladie du Québec (RAMQ).
  • In June 2021, Merck undertook the spinoff of Organon, establishing it as an autonomous Women's Health entity. This new company will focus on women's healthcare, encompassing a range of contraceptive and fertility brands, as well as offerings in dermatology, respiratory, and bone health products.
  • In April 2021, the United States Food and Drug Administration granted approval for Mayne Pharma's NEXTSTELLIS (comprising 3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) for pregnancy prevention.

Key Market Players

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.LTD.


Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Female Contraceptive Market, By Contraceptive Drugs:

o   Oral Contraceptives

o   Contraceptive Injections

o   Topical Contraceptives

o   Spermicides

  • Female Contraceptive Market, By Device:

o   Female Condoms

o   Diaphragms and Caps

o   Vaginal Rings

o   Contraceptive Sponges

o   Sub-dermal Contraceptive Implants

o   Intra Uterine Contraceptive Devices (IUCDs)

o   Others

  • Female Contraceptive Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

Global Female Contraceptive market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Female Contraceptive Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Female Contraceptive Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

5.2.2.    By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

5.2.3.    By Region

5.2.4.    By Company (2022)

5.3.  Product Market Map

5.3.1.    By Contraceptive Drugs

5.3.2.    By Device

5.3.3.    By Region

6.    North America Female Contraceptive Market Outlook

6.1.  Market Size & Forecast       

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

6.2.2.    By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

6.2.3.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Female Contraceptive Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Contraceptive Drugs

6.3.1.2.2.           By Device

6.3.2.    Canada Female Contraceptive Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Contraceptive Drugs

6.3.2.2.2.           By Device

6.3.3.    Mexico Female Contraceptive Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Contraceptive Drugs

6.3.3.2.2.           By Device

7.    Europe Female Contraceptive Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

7.2.2.    By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany Female Contraceptive Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Contraceptive Drugs

7.3.1.2.2.           By Device

7.3.2.    United Kingdom Female Contraceptive Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Contraceptive Drugs

7.3.2.2.2.           By Device

7.3.3.    France Female Contraceptive Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Contraceptive Drugs

7.3.3.2.2.           By Device

7.3.4.    Italy Female Contraceptive Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Contraceptive Drugs

7.3.4.2.2.           By Device

7.3.5.    Spain Female Contraceptive Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Contraceptive Drugs

7.3.5.2.2.           By Device

8.    Asia-Pacific Female Contraceptive Market Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

8.2.2.    By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

8.2.3.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Female Contraceptive Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Contraceptive Drugs

8.3.1.2.2.           By Device

8.3.2.    Japan Female Contraceptive Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Contraceptive Drugs

8.3.2.2.2.           By Device

8.3.3.    India Female Contraceptive Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Contraceptive Drugs

8.3.3.2.2.           By Device

8.3.4.    Australia Female Contraceptive Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Contraceptive Drugs

8.3.4.2.2.           By Device

8.3.5.    South Korea Female Contraceptive Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Contraceptive Drugs

8.3.5.2.2.           By Device

9.    South America Female Contraceptive Market Outlook

9.1.  Market Size & Forecast       

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

9.2.2.    By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

9.2.3.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Female Contraceptive Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Contraceptive Drugs

9.3.1.2.2.           By Device

9.3.2.    Argentina Female Contraceptive Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Contraceptive Drugs

9.3.2.2.2.           By Device

9.3.3.    Colombia Female Contraceptive Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Contraceptive Drugs

9.3.3.2.2.           By Device

10. Middle East and Africa Female Contraceptive Market Outlook

10.1.             Market Size & Forecast        

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)

10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)

10.2.3. By Country

10.3.             MEA: Country Analysis

10.3.1. South Africa Female Contraceptive Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Contraceptive Drugs

10.3.1.2.2.         By Device

10.3.2. Saudi Arabia Female Contraceptive Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Contraceptive Drugs

10.3.2.2.2.         By Device

10.3.3. UAE Female Contraceptive Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Contraceptive Drugs

10.3.3.2.2.         By Device

10.3.4. Kuwait Female Contraceptive Market Outlook

10.3.4.1.     Market Size & Forecast

10.3.4.1.1.         By Value

10.3.4.2.     Market Share & Forecast

10.3.4.2.1.         By Contraceptive Drugs

10.3.4.2.2.         By Device

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Development

12.2.             Mergers & Acquisitions

12.3.             Product Launches

13. Porter’s Five Forces Analysis

13.1.             Competition in the Industry

13.2.             Potential of New Entrants

13.3.             Power of Suppliers

13.4.             Power of Customers

13.5.             Threat of Substitute Products

14. Competitive Landscape

14.1.             Business Overview

14.2.             Product Offerings

14.3.             Recent Developments

14.4.             Financials (As Reported)

14.5.             Key Personnel

14.6.             SWOT Analysis

14.6.1.  Bayer AG

14.6.2.  Mayer Laboratories Inc

14.6.3.  Pfizer Inc

14.6.4.  Mylan Pharmaceuticals Inc

14.6.5.  Teva Pharmaceutical Industries Ltd

14.6.6.  Organon & Co.

14.6.7.  Agile Therapeutics Inc

14.6.8.  Lupin Pharmaceuticals Inc

14.6.9.  The Female Health Company

14.6.10.                FUJI LATEX CO.,LTD.

15.  Strategic Recommendations

About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Female Contraceptive Market was estimated to be USD 15.01 Billion in 2022.

down-arrow

Bayer AG, Mayer Laboratories Inc, Pfizer Inc, Mylan Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Organon & Co., Agile Therapeutics Inc, Lupin Pharmaceuticals Inc, The Female Health Company, FUJI LATEX CO.,LTD. are some of the key players operating in the Global Female Contraceptive Market.

down-arrow

Limited access and awareness, concerns related to product safety and potential side effects, regulatory hurdles, are some of the major challenges faced by the Global Female Contraceptive Market in the upcoming years.

down-arrow

Rising awareness and education regarding family planning and reproductive health and global health concerns such as the spread of sexually transmitted infections (STIs) and the Zika virus are the major drivers for the Global Female Contraceptive Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Female Contraceptive Market to Grow with a CAGR of 6.24% through 2028

Sep, 2023

Factors such as women and couples prioritizing family planning and reproductive health is expected to drive the Global Female Contraceptive Market growth in the forecast period, 2024-2028.

Why Choose Us